Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A

Junlong Li1, Medha Sasane2, Jing Zhao3

  • 1Analysis Group Inc., 111 Huntington Ave, Floor 14, Boston, MA, 02199, USA. junlong.li@analysisgroup.com.

Advances in Therapy
|June 28, 2018
PubMed
Abstract

Insights

The combination targeted therapy dabrafenib plus trametinib, along with immunotherapy agents pembrolizumab and nivolumab, demonstrated superior efficacy compared to chemotherapy for advanced non-small-cell lung cancer (NSCLC) patients in a network meta-analysis.

Area of Science:

  • Oncology
  • Medical Research
  • Pharmacology

Background:

  • Advanced or metastatic non-small-cell lung cancer (NSCLC) presents treatment challenges, particularly in the second-line setting.
  • The BRAF V600E mutation is rare, precluding randomized trials comparing targeted therapy dabrafenib plus trametinib with other second-line options.
  • A comprehensive assessment of comparative treatment efficacy is crucial for optimizing patient outcomes in previously treated advanced NSCLC.

Purpose of the Study:

  • To conduct a network meta-analysis (NMA) to compare the efficacy of various second-line treatments for advanced or metastatic NSCLC.
  • To evaluate treatments including dabrafenib plus trametinib, chemotherapy agents, immunotherapy, and best supportive care.
  • To assess overall response rates (ORR), disease control rates (DCR), progression-free survival (PFS), and overall survival (OS).

Main Methods:

  • A systematic literature review identified randomized trials for second-line or later treatments in advanced/metastatic NSCLC.
  • Network meta-analysis (NMA) was performed using logit models for ORR/DCR and fractional polynomial hazards models for PFS/OS.
  • Dabrafenib plus trametinib was indirectly compared to nivolumab via matching-adjusted indirect comparison.

Main Results:

  • Dabrafenib plus trametinib, pembrolizumab, and nivolumab showed significantly higher odds of achieving overall response compared to docetaxel.
  • Higher disease control rates were observed for dabrafenib plus trametinib, nintedanib plus docetaxel, and pemetrexed.
  • Patients receiving dabrafenib plus trametinib, nivolumab, or pembrolizumab experienced significantly lower hazards of disease progression and death at 6 months and 1 year, respectively, compared to docetaxel.

Conclusions:

  • In previously treated advanced or metastatic NSCLC, dabrafenib plus trametinib, pembrolizumab, and nivolumab are associated with improved efficacy.
  • These agents demonstrate higher overall response rates and prolonged progression-free and overall survival compared to chemotherapy.
  • The findings support the consideration of these targeted and immunotherapy options in the second-line treatment landscape for advanced NSCLC.

Related Concept Videos

Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
609
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Sample Preparation for Analysis: Advanced Techniques01:08

Sample Preparation for Analysis: Advanced Techniques

Accurate analysis of complex samples often requires advanced preparation techniques to achieve reliable and reproducible results. Samples containing inorganic or organic materials can be challenging to dissolve or decompose effectively. Standard sample preparation methods include acid digestion, fusion, dry ashing, and wet digestion.
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
1.5K
Lung Capacity01:47

Lung Capacity

The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.4K
Self-Efficacy01:29

Self-Efficacy

Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
233